Stock listing

NASDAQ:SLXN Silexion Therapeutics Corp Stock

Home listing (NASDAQ) of Silexion Therapeutics Corp

Follow Silexion Therapeutics Corp into a list and get an email when it puts out news.

Share price · NASDAQ:SLXN

$1.31 USD -0.13 (-9.0%)

Close on Nov 20, 2026

Past year -99.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.28 – $1.40 USDNov 20, 2026
Volume
15,877 sharesNov 20, 2026
Market cap
$790,001 USDAt the close on Nov 20, 2026 · price × 603,054 shares outstanding
52-week range
$1.28 – $777.12 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$166,262 USDMedian day 2,030 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Silexion Therapeutics Corp logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SLXN · Home$1.31 USD-0.13 (-9.0%)15,877$1.40$1.40$1.28$1.44Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SLXN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.31-0.13-9.0%$1.40$1.40$1.2815,877
$1.44-0.21-12.7%$1.61$1.65$1.4423,740
$1.65-0.11-6.3%$1.86$1.86$1.6121,779
$1.76-0.22-11.1%$1.98$1.98$1.7423,219
$1.98-0.68-25.6%$2.55$2.62$1.821103,100
$2.66-0.57-17.6%$3.105$3.24$2.6470,700
$3.23+0.614+23.5%$2.80$3.889$2.707291,800
$2.616-0.36-12.1%$2.928$2.928$2.56826,567
$2.976-0.504-14.5%$2.952$3.024$2.66440,542
$3.48+0.024+0.7%$3.648$3.648$3.456335
$3.456-0.24-6.5%$3.768$3.768$3.408210
$3.696+0.024+0.7%$3.672$3.792$3.624222
$3.672+0.12+3.4%$3.576$3.792$3.48356
$3.552+0.072+2.1%$3.624$3.696$3.48544
$3.48+0.072+2.1%$3.408$4.08$3.361,273
$3.408-0.264-7.2%$3.792$4.20$3.4081,037
$3.672-0.312-7.8%$4.08$4.08$3.624845
$3.984-0.216-5.1%$4.296$4.296$3.841,693
$4.20-0.336-7.4%$4.20$4.416$4.0325,934
$4.536+0.576+14.5%$4.056$4.68$3.8644,882
$3.960.000.0%$4.056$4.32$3.84946
$3.96+0.264+7.1%$4.104$4.104$3.84498
$3.696+0.024+0.7%$3.672$4.176$3.6721,943
$3.6720.000.0%$3.936$4.392$3.4088,891
$3.672-0.864-19.0%$4.656$4.656$3.6481,444
$4.536+0.432+10.5%$4.104$4.68$4.0324,912
$4.104-0.12-2.8%$4.32$4.32$3.9361,224
$4.224-0.048-1.1%$4.512$4.656$3.9123,625
$4.272-0.888-17.2%$4.992$4.992$4.2482,203
$5.16-0.48-8.5%$5.52$5.568$4.9921,426
$5.64-0.456-7.5%$5.904$6.00$5.3282,626
$6.096-0.216-3.4%$5.928$6.192$5.9041,867
$6.312-0.072-1.1%$6.456$6.456$6.0721,735
$6.384+0.144+2.3%$6.264$6.48$6.1682,142
$6.24-0.456-6.8%$6.48$7.176$6.243,516
$6.696+0.048+0.7%$6.192$7.008$5.9045,736
$6.648-0.984-12.9%$6.312$6.648$6.14420,314
$7.632+1.68+28.2%$7.656$9.60$7.152445,432
$5.952-0.288-4.6%$6.288$6.624$5.76134,374
$6.24+0.072+1.2%$5.76$6.48$5.6642,030
$6.168-1.392-18.4%$6.456$6.744$6.004,089
$7.56-1.848-19.6%$8.136$9.168$7.2014,500
$9.408-3.648-27.9%$11.81$12.00$7.87256,473
$13.06+2.592+24.8%$10.08$15.12$9.9634,944
$10.46+1.344+14.7%$9.264$10.78$9.21648,284
$9.12+0.96+11.8%$8.784$9.36$8.35214,787
$8.160.000.0%$8.16$8.376$7.7284,306
$8.16-1.08-11.7%$8.04$8.52$7.77664,181
$9.24+0.672+7.8%$8.352$9.60$8.2561,542
$8.568-1.584-15.6%$8.64$9.312$8.1364,476
$10.15+1.752+20.9%$9.96$11.69$9.24206,509
$8.40+0.12+1.4%$8.28$8.544$8.04116
$8.28-0.168-2.0%$8.736$8.736$8.04328
$8.4480.000.0%$8.928$9.12$8.448352
$8.448+0.024+0.3%$8.64$8.976$8.448221
$8.424-0.456-5.1%$9.12$9.36$8.40318
$8.880.000.0%$8.64$9.36$8.64309
$8.88+0.168+1.9%$8.856$9.024$8.64268
$8.712+0.072+0.8%$8.88$9.024$8.472134
$8.64+0.12+1.4%$8.40$9.12$8.40497
$8.52-0.24-2.7%$8.976$8.976$8.424397
$8.76-0.072-0.8%$8.64$8.928$8.544339
$8.832-0.624-6.6%$9.048$9.336$8.64471
$9.456-0.12-1.3%$9.336$9.744$9.048394
$9.576-0.336-3.4%$9.624$9.84$9.144488

Splits

4 splits since 2024 · NASDAQ:SLXN · every price before a split is adjusted for it

DayRatioWhat
1-for-24Consolidation
1-for-10Consolidation
1-for-15Consolidation
1-for-9Consolidation
Ticker
NASDAQ:SLXN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Silexion Therapeutics Corp news

Silexion Therapeutics Corp on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 59 in all · newest Nov 13, 2026 · oldest 2024
Decks
9 decks · latest Aug 10, 2026

Where Silexion Therapeutics Corp is listed

ListingExchangeCountryCurrency
NASDAQ:SLXN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SLXNBOATSUnited StatesUSD

Valuation

Price/book 0.3× against a median of 0.3×: 5th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$3.60M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
2.77

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Silexion Therapeutics Corp · NASDAQ:SLXNUS$790,001−US$3.60Mn/an/an/a0.3×n/a0.1×2.77
SureNano Science Ltd · CSE:SUREUS$1.17MUS$672,321n/an/an/a0.3×n/a0.0×0.25
Valion Bio, Inc. · NASDAQ:VBIOUS$1.04MUS$16.34Mn/a42.8×n/a0.2×n/a4.1×1.11
GeoVax Labs, Inc. · NASDAQ:GOVXUS$985,460−US$915,033n/an/an/a0.9×n/a0.2×1.47
Biodexa Pharmaceuticals plc · NASDAQ:BDRXUS$982,950−US$3.22Mn/an/an/a0.1×n/a0.0×1.01
Gabather AB · OMXSTO:GABAUS$920,657US$559,800n/an/an/a6.4×n/a0.0×n/a
ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2US$793,620−US$2.43Mn/a−6.5×n/a0.2×−935.9%0.0×n/a
Oragenics Inc. · AMEX:OGENUS$708,377−US$1.12Mn/an/an/a0.7×n/a0.4×1.47
Protagenic Therapeutics, Inc. · OTC:PTIXUS$687,879US$610,9700.1×n/an/a0.6×n/a0.0×1.21
Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABTUS$580,337−US$2.74Mn/an/an/a0.2×n/a0.0×0.46
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Median of the othersUS$857,139−US$177,6170.1×18.1×0.3×−935.9%0.0×1.16

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
120.00 USD · Analysts' mean
EPS, year to Dec 2026
-112.80 · 1 analyst

Team and board

Officers

OfficerRole
Mirit Horenshtein HadarChief Financial Officer
Michal YaronVP RA
Orit Pollack ShragaiVP Clinical Operations
Racheli Gabai-MalkaVP Pharmaceutical Development
Mitchell ShirvanChief Scientific and Development Officer

Board

DirectorRole
Ilan HadarChairman
Avner LushiDirector
Dror AbramovDirector
Ruth AlonDirector
Shlomo NoyDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026−38.7%
Q2 2026Aug 14, 2026 · Before open−8.7%
Q1 2026May 15, 2026 · After close−5.2%
Q4 2025Mar 18, 2026−7.8%
Q3 2025Nov 12, 2025 · Before open+3.6%
Q2 2025Aug 7, 2025 · After close−4.1%
Q1 2025May 13, 2025 · After close−0.9%
Q4 2024Mar 18, 2025 · After close−11.2%
Q3 2024Nov 14, 2024 · Before open−8.6%
Q2 2024Aug 13, 2024 · Before open−12.1%
All 19 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close0.0%
Q4 2022Mar 31, 2023+0.2%
Q3 2022Nov 14, 2022+0.1%
Q2 2022Aug 15, 20220.0%
Q1 2022May 23, 20220.0%
Q4 2021Mar 31, 2022+0.4%
Quarter to Sep 30, 2021Nov 9, 2021+0.2%
Quarter to Jun 30, 2021Aug 16, 2021−0.6%
Quarter to Mar 31, 2021May 25, 2021−0.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck27 slidesAug 10, 2026
Investor Presentation (February 2026)Investor deck34 slidesFeb 3, 2026
Investor Presentation (February 2026)Investor deck32 slidesFebruary 2026
Investor Presentation (August 2025)Investor deck32 slidesAugust 2025
Investor Presentation (March 2025)Investor deck32 slidesMarch 2025
Investor Presentation (January 2025)Investor deck31 slidesJan 15, 2025
Investor Presentation (December 2024)Investor deck33 slidesDecember 2024
Investor Presentation (September 2024)Investor deck30 slidesSep 9, 2024
SPAC Merger (July 2024)SPAC merger24 slidesJul 25, 2024

Open Decks

Financings

RaiseDate
Ordinary shares on exercise of series E warrants
Announced: US$837,366 · US$0.2603 a share · Warrants at US$0.2603 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital for general corporate purposes
Sep 29, 2026
Public offering of ordinary shares
Closed: US$2.5M raised · US$0.65 a share · Warrants at US$0.65 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Strengthen the balance sheet, support the Phase 2/3 trial of SIL204 and support Nasdaq continued listing compliance
Aug 14, 2026
Public offering of ordinary shares (or ordinary share equivalents) with series A and series B warrants
Announced: US$6M · US$4 a share · Warrants at US$4 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Advance pre-clinical studies and general corporate purposes
Sep 11, 2025
Warrant exercise of ordinary shares on exercise of warrants
Announced: about US$1.8M · US$11.57 a share · Warrants at US$11.32 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital for general corporate purposes
Aug 1, 2025
Warrant exercise of ordinary shares on exercise of outstanding warrants
Announced: about US$3.3M · US$1.35 a share · Warrants at US$1.5 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital for general corporate purposes
Jan 29, 2025
Public offering of ordinary shares (or ordinary share equivalents) and warrants
Announced: about US$5M · US$1.35 a share · Warrants at US$1.35 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Advance pre-clinical studies and general corporate purposes
Jan 15, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2012
Revenue0000
Cost of revenue14.0K25.0K
Gross profit-14.0K-25.0K
Research and development7.14M5.82M3.71M3.23M
Selling, general and administrative4.48M6.73M928.0K577.0K
Operating income-11.6M-12.6M-4.68M-3.86M-943.9K-195.9K
Depreciation and amortization14.0K25.0K45.0K57.0K2.00K
EBITDA-11.6M-12.5M-4.64M-3.80M
Interest expense13.0K52.0K9.00K85.0K
Income before tax-11.9M-16.5M-5.08M-3.46M-755.2K-195.9K
Income tax3.00K10.0K32.0K24.0K
Net income-11.9M-16.5M-5.11M-3.21M-755.2K-195.9K
Earnings per share, basic8.96394.9444.23-68.64-17.80
Earnings per share, diluted8.96394.9444.23

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2013FY2012
Cash and equivalents5.99M1.19M4.59M8.26M38.9K51.7K
Short-term investments35.0K
Receivables89.0K161.0K
Current assets6.64M2.25M4.98M8.84M407.8K51.7K928.0K1.79M
Property, plant and equipment25.0K30.0K49.0K9.00K7.00K
Total assets7.21M2.86M5.26M9.33M115.4M129.4K
Accounts payable787.0K929.0K319.0K240.0K102.0K81.0K
Current liabilities2.76M3.52M2.20M1.61M348.6K29.4K241.0K168.0K
Long-term debt1.57M2.96M
Total debt468.0K4.49M171.0K271.0K
Total liabilities4.61M6.85M2.25M16.4M508.9K299.4K
Shareholders' equity2.60M-3.99M-15.5M-10.7M114.9M-170.0K
Shares outstanding13.0K123.3M97.1M46511.0K11.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2012
Cash from operations-10.8M-8.40M-4.53M-3.33M-1.41M-75.0K-911.0K
Capital spending-9.00K-22.0K-12.0K-40.0K-40-3.00K
Free cash flow-10.8M-8.42M-4.54M-3.38M-1.41M-75.0K-914.0K
Cash from investing-14.0K-22.0K573.0K-524.0K-28.0K
Cash from financing15.6M5.10M522.0K2.75M116.4M126.7K1.72M
Change in cash4.81M-3.31M-3.43M-1.77M-12.8K51.7K782.0K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 19, 2026Current reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveNov 10, 2026Other filingsSEC
8-K · Current reportNov 9, 2026Current reportSEC
S-3 · Registration statementOct 28, 2026Offer documentSEC
8-K · Current reportOct 26, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialOct 19, 2026Meeting noticeSEC
DEF 14A · Proxy statementOct 5, 2026Meeting noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 30, 2026Current reportSEC
424B3 · ProspectusSep 29, 2026Offer documentSEC
8-K · Current reportSep 29, 2026Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 28, 2026Big-stake noticeSEC
8-K · Current reportSep 28, 2026Current reportSEC
8-K · Current reportSep 25, 2026Current reportSEC
PRE 14A · Preliminary proxy statementSep 25, 2026Meeting noticeSEC
8-K · Current reportSep 25, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialSep 16, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialSep 9, 2026Meeting noticeSEC
DEF 14A · Proxy statementAug 25, 2026Meeting noticeSEC
8-K · Current reportAug 21, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 19, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 18, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementAug 14, 2026Meeting noticeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
8-K · Current reportAug 13, 2026Current reportSEC
8-K · Current reportAug 13, 2026Material contractSEC
424B4 · ProspectusAug 13, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveAug 12, 2026Other filingsSEC
S-1/A · Registration statement, amendedAug 10, 2026Offer documentSEC
8-K · Current reportAug 10, 2026Current reportSEC
S-1 · Registration statementAug 7, 2026Offer documentSEC
8-K · Current reportAug 4, 2026Current reportSEC
8-K · Current reportAug 3, 2026Current reportSEC
8-K · Current reportJul 31, 2026Management or board changeSEC
8-K · Current reportJul 29, 2026Current reportSEC
8-K · Current reportJul 21, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialJul 13, 2026Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 23, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJun 22, 2026Other filingsSEC
424B3 · ProspectusJun 18, 2026Offer documentSEC
DEF 14A · Proxy statementJun 16, 2026Meeting noticeSEC
CORRESP · Letter to the SECJun 16, 2026Other filingsSEC
UPLOAD · Letter from the SECJun 15, 2026Other filingsSEC
S-3 · Registration statementJun 12, 2026Offer documentSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementJun 3, 2026Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 29, 2026Big-stake noticeSEC
8-K · Current reportMay 29, 2026Current reportSEC
S-8 · Registration statement for employee plansMay 28, 2026Offer documentSEC
8-K · Current reportMay 26, 2026Current reportSEC
10-K/A · Annual report, amendedMay 19, 2026Annual reportSEC
8-K · Current reportMay 18, 2026ResultsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 15, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 14, 2026Current reportSEC
8-K · Current reportMay 13, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMay 12, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveMay 12, 2026Other filingsSEC
POS AM · Amendment to an effective registrationMay 7, 2026Offer documentSEC
POS AM · Amendment to an effective registrationMay 7, 2026Offer documentSEC
8-K · Current reportMay 5, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
8-K · Current reportApr 28, 2026Current reportSEC
DEF 14A · Proxy statementApr 9, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 31, 2026Meeting noticeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
8-K · Current reportMar 25, 2026Management or board changeSEC
8-K · Current reportMar 24, 2026Current reportSEC
8-K · Current reportMar 23, 2026Meeting outcomeSEC
DRS · Draft registration statementMar 17, 2026Offer documentSEC
10-K · Annual reportMar 17, 2026Annual reportSEC
DEFA14A · Additional proxy materialMar 16, 2026Meeting noticeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
DEF 14A · Proxy statementFeb 23, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansFeb 19, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementFeb 13, 2026Meeting noticeSEC
8-K · Current reportFeb 3, 2026Current reportSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
8-K · Current reportJan 6, 2026Current reportSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
8-K · Current reportDec 16, 2025Current reportSEC
8-K · Current reportDec 2, 2025Current reportSEC
8-K · Current reportNov 25, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 12, 2025ResultsSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
S-3 · Registration statementOct 31, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 1, 2025Other filingsSEC
8-K · Current reportSep 30, 2025Current reportSEC
CORRESP · Letter to the SECSep 30, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 29, 2025Other filingsSEC
S-3 · Registration statementSep 26, 2025Offer documentSEC
8-K · Current reportSep 26, 2025Material contractSEC
8-K · Current reportSep 25, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 23, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 18, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 17, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 15, 2025Big-stake noticeSEC
8-K · Current reportSep 15, 2025FinancingSEC
SCHEDULE 13G · Big-stake noticeSep 15, 2025Big-stake noticeSEC
8-K · Current reportSep 12, 2025Material contractSEC
424B4 · ProspectusSep 12, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 12, 2025Other filingsSEC
8-K · Current reportSep 11, 2025Current reportSEC
CORRESP · Letter to the SECSep 9, 2025Other filingsSEC
CORRESP · Letter to the SECSep 9, 2025Other filingsSEC
S-1 · Registration statementSep 5, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 5, 2025Other filingsSEC
8-K · Current reportSep 4, 2025Current reportSEC
424B3 · ProspectusSep 4, 2025Offer documentSEC
8-K · Current reportSep 2, 2025Current reportSEC
CORRESP · Letter to the SECSep 2, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 28, 2025Other filingsSEC
S-1 · Registration statementAug 26, 2025Offer documentSEC
S-8 · Registration statement for employee plansAug 20, 2025Offer documentSEC
8-K · Current reportAug 20, 2025Current reportSEC
8-K · Current reportAug 19, 2025Meeting outcomeSEC
424B3 · ProspectusAug 12, 2025Offer documentSEC
424B3 · ProspectusAug 12, 2025Offer documentSEC
424B3 · ProspectusAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialAug 12, 2025Meeting noticeSEC
8-K · Current reportAug 12, 2025ResultsSEC
DAug 11, 2025Other filingsSEC
8-K · Current reportAug 1, 2025Material contractSEC
424B3 · ProspectusAug 1, 2025Offer documentSEC
424B3 · ProspectusAug 1, 2025Offer documentSEC
8-K · Current reportJul 31, 2025Current reportSEC
DEF 14A · Proxy statementJul 31, 2025Meeting noticeSEC
8-K · Current reportJul 29, 2025Current reportSEC
8-K · Current reportJul 21, 2025Current reportSEC
PRE 14A · Preliminary proxy statementJul 21, 2025Meeting noticeSEC
8-K · Current reportJul 16, 2025Current reportSEC
8-K · Current reportJul 14, 2025Meeting outcomeSEC
8-K · Current reportJul 9, 2025Current reportSEC
8-K/A · Current report, amendedJul 8, 2025Current reportSEC
8-K · Current reportJul 8, 2025Current reportSEC
DEFA14A · Additional proxy materialJul 7, 2025Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 26, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialJun 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementJun 16, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementJun 5, 2025Meeting noticeSEC
8-K · Current reportJun 3, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveMay 30, 2025Other filingsSEC
8-K · Current reportMay 29, 2025Current reportSEC
POS AM · Amendment to an effective registrationMay 28, 2025Offer documentSEC
8-K · Current reportMay 23, 2025Current reportSEC
8-K · Current reportMay 21, 2025Current reportSEC
424B3 · ProspectusMay 13, 2025Offer documentSEC
424B3 · ProspectusMay 13, 2025Offer documentSEC
8-K · Current reportMay 13, 2025ResultsSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
424B3 · ProspectusMay 6, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 2, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 29, 2025Offer documentSEC
AWApr 29, 2025Other filingsSEC
AWApr 29, 2025Other filingsSEC
424B3 · ProspectusApr 29, 2025Offer documentSEC
UPLOAD · Letter from the SECApr 28, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 28, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 23, 2025Offer documentSEC
8-K · Current reportApr 23, 2025Current reportSEC
DRS · Draft registration statementApr 23, 2025Offer documentSEC
POS AM · Amendment to an effective registrationApr 10, 2025Offer documentSEC
POS AM · Amendment to an effective registrationApr 10, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 2, 2025Other filingsSEC
424B3 · ProspectusApr 1, 2025Offer documentSEC
CORRESP · Letter to the SECApr 1, 2025Other filingsSEC
8-K · Current reportMar 28, 2025Current reportSEC
S-1/A · Registration statement, amendedMar 27, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 18, 2025Offer documentSEC
8-K · Current reportMar 18, 2025ResultsSEC
10-K · Annual reportMar 18, 2025Annual reportSEC
424B3 · ProspectusMar 14, 2025Offer documentSEC
8-K · Current reportMar 14, 2025Material contractSEC
8-K · Current reportMar 5, 2025Current reportSEC
UPLOAD · Letter from the SECFeb 19, 2025Other filingsSEC
S-1 · Registration statementFeb 12, 2025Offer documentSEC

This page holds 200 of 285 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Silexion Therapeutics Corp’s releases · as of Nov 11, 2026

Common shares
603,054
Fully diluted
603,054

Fully diluted

LineSharesAs of
Common shares603,054Nov 11, 2026

Warrants and options

Lot
Warrants · US$0.65 · expire about Aug 2031

Share count over time

CountShares
Nov 11, 2026603,054
Nov 11, 2026
Nov 9, 2026
Sep 30, 2026603,055
May 26, 2026

Open Cap table

Shareholders

StakeStakeSharesDateFiling
Moringa Sponsor, LP17.70%1.95MSep 18, 2026Schedule 13D
Orca Capital AG6.20%131KSep 11, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ruth Alon
Other companies: Alpha Tau Medical Ltd (Director · Since at least Mar 18, 2026); Vascular Biogenics Ltd (Director · Jan 1, 2023 – Jan 1, 2023 · Past); Moringa Acquisition Corp (Director · Feb 16, 2021 – Feb 16, 2021 · Past); Chemomab Therapeutics Ltd. (Director · Jan 1, 2020 – Jan 1, 2020 · Past)
Director · Since at least Aug 15, 2024
Avner Lushi
Other companies: BrainsWay Ltd (Director · Since at least Mar 18, 2026)
Director · Since at least Aug 15, 2024
Ilan Levin
Other companies: Moringa Acquisition Corp (Chairman and CEO, Director · Feb 16, 2021 – Feb 16, 2021 · Past)
Director · Since at least Aug 15, 2024
Amnon PeledDirector · Since at least Dec 10, 2024
Dror AbramovDirector · Since at least Aug 15, 2024
Hadar Mirit HorenshteinCFO and Secretary · Since at least Aug 15, 2024
Ilan HadarChairman · Since at least Aug 15, 2024
Ilan ShiloahDirector · Aug 15, 2024 – Aug 15, 2024 · Past
Michal YaronVP RA · Since at least Nov 4, 2026
Mirit Horenshtein HadarChief Financial Officer · Since at least Sep 9, 2026
All 15 people
PersonSeat
Mitchell ShirvanChief Scientific and Development Officer · Since at least Aug 15, 2024
Orit Pollack ShragaiVP Clinical Operations · Since at least Nov 4, 2026
Racheli Gabai-MalkaVP Pharmaceutical Development · Since at least Nov 4, 2026
Shlomo NoyDirector · Since at least Aug 15, 2024
Silexion Therapeutics CorpMs. Mirit Horenshtein HadarCapital Markets Advisors for Silexion · Jan 15, 2025 – Nov 4, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Silexion Therapeutics Corp.